Platelet-rich plasma treatment for corneal nerve damage
Part of Eyes & vision clinical trials.
This trial studies whether your own platelet-rich plasma can help heal a fragile, slow-to-recover cornea caused by reduced corneal feeling (nerve damage). It may help reduce corneal erosion and improve corneal surface healing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have neurotrophic keratopathy, confirmed by low corneal sensitivity testing (≤ 3 cm on an esthesiometer).
- You currently have corneal erosions (areas of the cornea that keep breaking down).
- Your condition is caused by one of these: diabetes, herpes-related eye infection, other infections that left scars, limbal stem cell problems, or certain chemical/thermal burns or injuries, with recovery time of at least 3 months.
- If your eye problem was due to surgery or injury, it must have happened at least 3 months before starting the trial.
- You are not pregnant and can take part without needing to be considered “homeless” or a “migrant” for study purposes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether a 0.1% RGN-259 eye drop can safely improve a stubborn corneal wound in adults with neurotrophic keratopathy (nerve-related corneal healing problems). You may qualify if you still have an eye surface defect after at least a week of standard treatments, and you meet specific measurements for corneal sensitivity and vision.
This trial studies injecting your own platelet-rich plasma into the eye to help a persistent corneal surface defect heal. It may help if you have a recurring or nerve-related corneal ulcer, but it’s not for certain ulcer types or active eye infections.
This trial tests an experimental eye drop (STSP-0902) for a condition called neurotrophic keratitis, where the cornea (the clear front part of the eye) gets scratches or sores because nerves are damaged. The drop contains a growth factor to help the eye heal. You might be eligible if you have a persistent scratch or sore on your cornea that has not improved for at least a week.
This trial tests whether a new eye drop called Lacripep can help treat neurotrophic keratitis, a rare eye condition where the cornea loses sensation and can become damaged. The study compares Lacripep to a placebo (inactive) drop to see if it improves corneal healing and vision.
This study tests whether adding platelet-rich plasma (a concentrate from your own blood that may help healing) to a standard pulsed radiofrequency procedure reduces pain from infraorbital neuralgia more effectively than radiofrequency alone. It involves two treatments and follow-up for several months.
This trial tests whether special eye drops made from cord plasma (a blood product) can reduce chronic eye pain caused by damaged nerves in the cornea (the clear front part of your eye). You may qualify if you have had eye pain for at least 3 months without obvious surface damage.
Hear when a new Neurotrophic Keratopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.